Property	Value
Status
Version
Ad File
Disable Ads Flag
Environment
Moat Init
Moat Ready
Contextual Ready
Contextual URL
Contextual Initial Segments
Contextual Used Segments
AdUnit
SubAdUnit
Custom Targeting
Ad Events
Invalid Ad Sizes

Published in Multiple Sclerosis and

Journal Scan / Review · November 14, 2023

Effect of Disease-Modifying Therapies on Fatigue in Patients With MS

Multiple Sclerosis and Related Disorders

Save Recommend

Sign in to PracticeUpdate

Only registered members have full access to PracticeUpdate content.

Sign in

Not a member?

Join for free

Disclosure statements are available on the authors' profiles:

Ahmed Obeidat MD, PhD

Multiple Sclerosis and Related Disorders

The effect of disease modifying therapies on fatigue in multiple sclerosis

Mult Scler Relat Disord 2023 Nov 01;79(xx)105065, S Cruz Rivera, OL Aiyegbusi, D Piani Meier, A Dunne, DE Harlow, C Henke, P Kamudoni, MJ Calvert

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

story of the week

Yet Another Study Supporting Extended-Interval Ocrelizumab Dosing in Patients With MS

Mult. Scler. · November 27, 2023
story of the week

Ocrelizumab Exposure in Relapsing–Remitting MS

J Neurol · November 21, 2023
story of the week

Recurrence of Severe Symptomatic Late-Onset Neutropenia Related to Ocrelizumab Therapy

Mult. Scler. · November 15, 2023
story of the week

Odour Discrimination and Identification as a Biomarker of Long-Term Disability Worsening in Patients With MS

Mult. Scler. · November 07, 2023
story of the week

Increasing Neurofilament Light Chain and Glial Fibrillary Acidic Protein Levels After Treatment Discontinuation Predict MS Disease Activity

Neurol Neuroimmunol Neuroinflamm · October 31, 2023
story of the week

Extended-Interval Dosing of Ocrelizumab Modifies the Repopulation of B Cells Without Altering the Clinical Efficacy in Patients With MS

J Neuroinflammation · October 23, 2023
story of the week

Isolated Cognitive Relapses Do Exist in Patients With MS

Mult. Scler. · October 16, 2023
story of the week

Are Clinicians Overdosing Anti-CD20 Agents in Patients With MS?

Neurol Neuroimmunol Neuroinflamm · October 09, 2023
story of the week

MOG Antibodies in Adults With a First Demyelinating Event Suggestive of MS

Ann. Neurol · October 03, 2023
featured

Nailing Your Personal Statement

Early Career · September 28, 2023
story of the week

Natalizumab Immunogenicity Evaluation in Patients With Infusion-Related Events or Disease Exacerbations

Front Immunol · September 25, 2023

Multiple Sclerosis

Effect of Disease-Modifying Therapies on Fatigue in Patients With MS

Additional Info

The effect of disease modifying therapies on fatigue in multiple sclerosis

Further Reading

Yet Another Study Supporting Extended-Interval Ocrelizumab Dosing in Patients With MS

Ocrelizumab Exposure in Relapsing–Remitting MS

Recurrence of Severe Symptomatic Late-Onset Neutropenia Related to Ocrelizumab Therapy

Odour Discrimination and Identification as a Biomarker of Long-Term Disability Worsening in Patients With MS

Increasing Neurofilament Light Chain and Glial Fibrillary Acidic Protein Levels After Treatment Discontinuation Predict MS Disease Activity

Extended-Interval Dosing of Ocrelizumab Modifies the Repopulation of B Cells Without Altering the Clinical Efficacy in Patients With MS

Isolated Cognitive Relapses Do Exist in Patients With MS

Are Clinicians Overdosing Anti-CD20 Agents in Patients With MS?

MOG Antibodies in Adults With a First Demyelinating Event Suggestive of MS

Nailing Your Personal Statement

Natalizumab Immunogenicity Evaluation in Patients With Infusion-Related Events or Disease Exacerbations

Recently Updated